{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-027728","form_type":"8-K","ticker":"SIGY","cik":"0001642159","company_name":"Sigyn Therapeutics, Inc.","filed_at":"2022-10-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.540297+00:00","generated_at":"2026-06-23T05:22:46.792698+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sigyn Therapeutics appoints Jim Dorst, Richa Nand, and Christopher Wetzel to Board","bullets":["Appointments effective October 10, 2022; each director brings distinct expertise.","Jim Dorst: 30+ years finance/operations; former Director of Corporate Development at SYNNEX/Concentrix and CFO of Aethlon Medical.","Richa Nand: IP attorney and founder of Insight Patents; biomedical researcher background at Cedars Sinai.","Christopher Wetzel: CEO of Surgery Center at Hamilton since 2004; long-term investor in extracorporeal therapy.","Board cited each director's experience in financial expertise, IP, or healthcare delivery as qualification."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-027728","json":"https://secwatch.observer/filing/0001493152-22-027728.json","markdown":"https://secwatch.observer/filing/0001493152-22-027728.md","text":"https://secwatch.observer/filing/0001493152-22-027728.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642159/000149315222027728/0001493152-22-027728-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642159/000149315222027728/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T05:22:46.792698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"517b4f4270","claim":"Jim Dorst was appointed as Director at Sigyn Therapeutics, Inc..","evidence_excerpt":"The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642159/000149315222027728/0001493152-22-027728-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7b4d009c82","claim":"Christopher Wetzel was appointed as Director at Sigyn Therapeutics, Inc..","evidence_excerpt":"The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642159/000149315222027728/0001493152-22-027728-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"cb6d32fdce","claim":"Richa Nand was appointed as Director at Sigyn Therapeutics, Inc..","evidence_excerpt":"The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642159/000149315222027728/0001493152-22-027728-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}